Results 221 to 230 of about 82,336 (259)
Some of the next articles are maybe not open access.
Clinical Reviews in Allergy & Immunology, 2003
Infections are common in systemic lupus erythematosus (SLE), and remain a source of mortality. The types of infections (such as pneumonia, urinary tract infection, cellulitis, and sepsis) in SLE patients are similar to the general population and include the same pathogens (Gram-positive and Gram-negative).
Gisele, Zandman-Goddard +1 more
openaire +2 more sources
Infections are common in systemic lupus erythematosus (SLE), and remain a source of mortality. The types of infections (such as pneumonia, urinary tract infection, cellulitis, and sepsis) in SLE patients are similar to the general population and include the same pathogens (Gram-positive and Gram-negative).
Gisele, Zandman-Goddard +1 more
openaire +2 more sources
Orbit, 2018
In systemic lupus erythematosus, ophthalmic manifestations are noted in up to one-third of patients. We describe a patient with an unusual initial presentation of this disorder.
Yu-Chieh, Hung +4 more
openaire +2 more sources
In systemic lupus erythematosus, ophthalmic manifestations are noted in up to one-third of patients. We describe a patient with an unusual initial presentation of this disorder.
Yu-Chieh, Hung +4 more
openaire +2 more sources
Clinics in Rheumatic Diseases, 1982
SUMMARY AND CONCLUSIONS The growing number of anecdotal reports on the effect of plasmapheresis in patients with active SLE suggests that plasmapheresis, particularly in combination with cytotoxic drugs, merits further exploration as a therapeutic modality.
openaire +2 more sources
SUMMARY AND CONCLUSIONS The growing number of anecdotal reports on the effect of plasmapheresis in patients with active SLE suggests that plasmapheresis, particularly in combination with cytotoxic drugs, merits further exploration as a therapeutic modality.
openaire +2 more sources
Recent Patents on Inflammation & Allergy Drug Discovery, 2008
The therapy of systemic lupus erythematosus (SLE), a systemic autoimmune disease of unknown aetiology, is significantly complicated by the diversity of disease manifestations and by a variety of complex immune abnormalities. Recent preclinical studies have shown the therapeutic efficacy of several drugs and/or new compounds, some of which have been ...
FERRERA, FRANCESCA +6 more
openaire +4 more sources
The therapy of systemic lupus erythematosus (SLE), a systemic autoimmune disease of unknown aetiology, is significantly complicated by the diversity of disease manifestations and by a variety of complex immune abnormalities. Recent preclinical studies have shown the therapeutic efficacy of several drugs and/or new compounds, some of which have been ...
FERRERA, FRANCESCA +6 more
openaire +4 more sources
Best Practice & Research Clinical Rheumatology, 2002
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease, as yet of unknown aetiology, with diverse clinical manifestations and a variable course and prognosis. The diagnosis is based on recognizing the overall pattern of clinical and laboratory abnormalities.
openaire +2 more sources
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease, as yet of unknown aetiology, with diverse clinical manifestations and a variable course and prognosis. The diagnosis is based on recognizing the overall pattern of clinical and laboratory abnormalities.
openaire +2 more sources
Best Practice & Research Clinical Rheumatology, 2017
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that affects many different organ systems, with excessive production of type I interferons (IFNs) and autoantibodies against nucleic acids as hallmarks. Activation of the type I IFN system in SLE is due to continuous stimulation of plasmacytoid dendritic cells by endogenous
Bengtsson AA, Rönnblom L
openaire +3 more sources
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that affects many different organ systems, with excessive production of type I interferons (IFNs) and autoantibodies against nucleic acids as hallmarks. Activation of the type I IFN system in SLE is due to continuous stimulation of plasmacytoid dendritic cells by endogenous
Bengtsson AA, Rönnblom L
openaire +3 more sources
Lupus, 2016
Throughout the 20th century, a remarkable improvement in the prognosis of systemic lupus erythematosus (SLE) has been seen, mostly due to a better understanding of the disease and the advent of new therapies. However, a plateau seems to have been reached. Whilst outcomes related to active disease have greatly improved, damage accrual tends to be slowly
A, Ugarte, G, Ruiz-Irastorza
openaire +2 more sources
Throughout the 20th century, a remarkable improvement in the prognosis of systemic lupus erythematosus (SLE) has been seen, mostly due to a better understanding of the disease and the advent of new therapies. However, a plateau seems to have been reached. Whilst outcomes related to active disease have greatly improved, damage accrual tends to be slowly
A, Ugarte, G, Ruiz-Irastorza
openaire +2 more sources
Springer Seminars in Immunopathology, 2006
Genetic studies in spontaneous, induced, and gene-manipulated mouse models of SLE have provided significant insights into the potential number and diversity of genes that can promote, resist, and modify lupus susceptibility. Novel genes and mechanisms of disease pathogenesis have also been identified.
Dwight H, Kono +1 more
openaire +2 more sources
Genetic studies in spontaneous, induced, and gene-manipulated mouse models of SLE have provided significant insights into the potential number and diversity of genes that can promote, resist, and modify lupus susceptibility. Novel genes and mechanisms of disease pathogenesis have also been identified.
Dwight H, Kono +1 more
openaire +2 more sources
Clinics in Rheumatic Diseases, 1982
M J, Walport, C M, Black, J R, Batchelor
openaire +2 more sources
M J, Walport, C M, Black, J R, Batchelor
openaire +2 more sources
2018
In this project, 877 systemic lupus erythematosus patients were amplified for TCRB repertoires and sequenced by high-throughput sequencer. All samples are Chinese people.
openaire +1 more source
In this project, 877 systemic lupus erythematosus patients were amplified for TCRB repertoires and sequenced by high-throughput sequencer. All samples are Chinese people.
openaire +1 more source